New Therapeutic Targets TIGIT, LAG-3 and TIM-3 in the Treatment of Advanced, Non-Small-Cell Lung Cancer
International Journal of Molecular Sciences · 25.04.2025 · 26 (9) · 4096
DOI: 10.3390/ijms26094096 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift International Journal of Molecular Sciences, online erschienen am 25.04.2025. Verfasst von Jacek Kabut und 2 weiteren Autor:innen. Beteiligte Einrichtung: Department of Oncology and Radiotherapy, Medical University of Silesia, 40-514 Katowice, Poland. Hauptthemen laut MEDLINE: Hepatitis A Virus Cellular Receptor 2, Lung Neoplasms, Receptors, Immunologic, Carcinoma, Non-Small-Cell Lung. Die Arbeit wurde bisher 11-mal zitiert (Crossref) und nennt 73 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Medical University of Silesia, Katowice, Poland.
Abstract (Originalsprache)
The introduction of immunotherapy and target therapy into clinical practice has become a chance for many patients with cancer to prolong their survival while maintaining optimal quality of life. Treatment of lung cancer is excellent evidence of the progress of medical therapies. An understanding of the mechanisms of tumor development has led to the evolution of new methods of treatment. Immunoreceptors of T cells with the immunoglobulin domain ITIM, TIM-3 (T-cell immunoglobulin- and mucin domain-3-containing molecule 3), and LAG-3 (lymphocyte activation gene-3) represent new interesting therapeutic targets. The combination of anti-PD-1 and anti-CTLA-4 blockade has proven the possibility of strengthening the anti-tumor response by acting via two separate mechanisms. Adding additional checkpoints to the PD-1 blockade offers hope for further improvements in the effects of the treatment of patients and expanding the group responding to immunotherapy. This paper presents new promising molecular targets along with studies demonstrating the treatment results using them.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Oncology and Radiotherapy, Medical University of Silesia, 40-514 Katowice, Poland.
ORCID-Profile: Anita Gorzelak-Magiera, Iwona Gisterek-Grocholska
Förderung
- Medical University of Silesia, Katowice, Poland
Zitieren
APA
Kabut, J., Gorzelak-Magiera, A., & Gisterek-Grocholska, I. (2025). New Therapeutic Targets TIGIT, LAG-3 and TIM-3 in the Treatment of Advanced, Non-Small-Cell Lung Cancer. International Journal of Molecular Sciences, 26(9), 4096. https://doi.org/10.3390/ijms26094096
Vancouver
Kabut J, Gorzelak-Magiera A, Gisterek-Grocholska I. New Therapeutic Targets TIGIT, LAG-3 and TIM-3 in the Treatment of Advanced, Non-Small-Cell Lung Cancer. International Journal of Molecular Sciences. 2025;26(9):4096. doi:10.3390/ijms26094096
BibTeX
@article{Kabut2025,
author = {Kabut, Jacek and Gorzelak-Magiera, Anita and Gisterek-Grocholska, Iwona},
title = {New Therapeutic Targets TIGIT, LAG-3 and TIM-3 in the Treatment of Advanced, Non-Small-Cell Lung Cancer},
journal = {International Journal of Molecular Sciences},
year = {2025},
volume = {26},
number = {9},
pages = {4096},
doi = {10.3390/ijms26094096}
}
EUVIMED